162 related articles for article (PubMed ID: 20473871)
1. Plasma insulin-like growth factor 1 is positively associated with low-grade prostate cancer in the Health Professionals Follow-up Study 1993-2004.
Nimptsch K; Platz EA; Pollak MN; Kenfield SA; Stampfer MJ; Willett WC; Giovannucci E
Int J Cancer; 2011 Feb; 128(3):660-7. PubMed ID: 20473871
[TBL] [Abstract][Full Text] [Related]
2. Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era.
Platz EA; Pollak MN; Leitzmann MF; Stampfer MJ; Willett WC; Giovannucci E
Cancer Causes Control; 2005 Apr; 16(3):255-62. PubMed ID: 15947877
[TBL] [Abstract][Full Text] [Related]
3. Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition.
Allen NE; Key TJ; Appleby PN; Travis RC; Roddam AW; Rinaldi S; Egevad L; Rohrmann S; Linseisen J; Pischon T; Boeing H; Johnsen NF; Tjønneland A; Grønbaek H; Overvad K; Kiemeney L; Bueno-de-Mesquita HB; Bingham S; Khaw KT; Tumino R; Berrino F; Mattiello A; Sacerdote C; Palli D; Quirós JR; Ardanaz E; Navarro C; Larrañaga N; Gonzalez C; Sanchez MJ; Trichopoulou A; Travezea C; Trichopoulos D; Jenab M; Ferrari P; Riboli E; Kaaks R
Cancer Epidemiol Biomarkers Prev; 2007 Jun; 16(6):1121-7. PubMed ID: 17548673
[TBL] [Abstract][Full Text] [Related]
4. Insulin-like growth factors and prostate cancer: a population-based case-control study in China.
Chokkalingam AP; Pollak M; Fillmore CM; Gao YT; Stanczyk FZ; Deng J; Sesterhenn IA; Mostofi FK; Fears TR; Madigan MP; Ziegler RG; Fraumeni JF; Hsing AW
Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):421-7. PubMed ID: 11352850
[TBL] [Abstract][Full Text] [Related]
5. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer.
Chan JM; Stampfer MJ; Ma J; Gann P; Gaziano JM; Pollak M; Giovannucci E
J Natl Cancer Inst; 2002 Jul; 94(14):1099-106. PubMed ID: 12122101
[TBL] [Abstract][Full Text] [Related]
6. Circulating Insulin-Like Growth Factor 1-Related Biomarkers and Risk of Lethal Prostate Cancer.
Ma C; Wang Y; Wilson KM; Mucci LA; Stampfer MJ; Pollak M; Penney KL
JNCI Cancer Spectr; 2022 Feb; 6(1):. PubMed ID: 35047751
[TBL] [Abstract][Full Text] [Related]
7. Relation of serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States).
Li L; Yu H; Schumacher F; Casey G; Witte JS
Cancer Causes Control; 2003 Oct; 14(8):721-6. PubMed ID: 14674736
[TBL] [Abstract][Full Text] [Related]
8. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study.
Stattin P; Bylund A; Rinaldi S; Biessy C; Déchaud H; Stenman UH; Egevad L; Riboli E; Hallmans G; Kaaks R
J Natl Cancer Inst; 2000 Dec; 92(23):1910-7. PubMed ID: 11106682
[TBL] [Abstract][Full Text] [Related]
9. High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort.
Stattin P; Rinaldi S; Biessy C; Stenman UH; Hallmans G; Kaaks R
J Clin Oncol; 2004 Aug; 22(15):3104-12. PubMed ID: 15284261
[TBL] [Abstract][Full Text] [Related]
10. Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis.
Shariat SF; Lamb DJ; Kattan MW; Nguyen C; Kim J; Beck J; Wheeler TM; Slawin KM
J Clin Oncol; 2002 Feb; 20(3):833-41. PubMed ID: 11821468
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer risk in relation to insulin-like growth factor (IGF)-I and IGF-binding protein-3: A nested case-control study in large scale cohort study in Japan.
Mikami K; Ozasa K; Nakao M; Miki T; Hayashi K; Watanabe Y; Mori M; Sakauchi F; Washio M; Kubo T; Suzuki K; Wakai K; Nakachi K; Tajima K; Ito Y; Inaba Y; Tamakoshi A;
Asian Pac J Cancer Prev; 2009 Dec; 10 Suppl():57-61. PubMed ID: 20553083
[TBL] [Abstract][Full Text] [Related]
12. Levels of insulin-like growth factor I (IGF-I) and IGF binding proteins 2 and 3 in serial postoperative serum samples and risk of prostate cancer recurrence.
Yu H; Nicar MR; Shi R; Berkel HJ; Nam R; Trachtenberg J; Diamandis EP
Urology; 2001 Mar; 57(3):471-5. PubMed ID: 11248622
[TBL] [Abstract][Full Text] [Related]
13. Insulin-like growth factor-I concentration and risk of prostate cancer: results from the European Prospective Investigation into Cancer and Nutrition.
Price AJ; Allen NE; Appleby PN; Crowe FL; Travis RC; Tipper SJ; Overvad K; Grønbæk H; Tjønneland A; Johnsen NF; Rinaldi S; Kaaks R; Lukanova A; Boeing H; Aleksandrova K; Trichopoulou A; Trichopoulos D; Andarakis G; Palli D; Krogh V; Tumino R; Sacerdote C; Bueno-de-Mesquita HB; Argüelles MV; Sánchez MJ; Chirlaque MD; Barricarte A; Larrañaga N; González CA; Stattin P; Johansson M; Khaw KT; Wareham N; Gunter M; Riboli E; Key T
Cancer Epidemiol Biomarkers Prev; 2012 Sep; 21(9):1531-41. PubMed ID: 22761305
[TBL] [Abstract][Full Text] [Related]
14. Association between serum levels of insulin-like growth factor-1, bioavailable testosterone, and pathologic Gleason score.
Kim M; Kim JW; Kim JK; Lee SM; Song C; Jeong IG; Hong JH; Kim CS; Ahn H
Cancer Med; 2018 Aug; 7(8):4170-4180. PubMed ID: 29992746
[TBL] [Abstract][Full Text] [Related]
15. Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in benign prostatic hyperplasia and prostate cancer.
Khosravi J; Diamandi A; Mistry J; Scorilas A
J Clin Endocrinol Metab; 2001 Feb; 86(2):694-9. PubMed ID: 11158033
[TBL] [Abstract][Full Text] [Related]
16. Plasma levels of acid-labile subunit, free insulin-like growth factor-I, and prostate cancer risk: a prospective study.
Mucci LA; Stark JR; Pollak MN; Li H; Kurth T; Stampfer MJ; Ma J
Cancer Epidemiol Biomarkers Prev; 2010 Feb; 19(2):484-91. PubMed ID: 20142246
[TBL] [Abstract][Full Text] [Related]
17. Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin.
Chen C; Lewis SK; Voigt L; Fitzpatrick A; Plymate SR; Weiss NS
Cancer; 2005 Jan; 103(1):76-84. PubMed ID: 15540247
[TBL] [Abstract][Full Text] [Related]
18. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study.
Wolk A; Mantzoros CS; Andersson SO; Bergström R; Signorello LB; Lagiou P; Adami HO; Trichopoulos D
J Natl Cancer Inst; 1998 Jun; 90(12):911-5. PubMed ID: 9637140
[TBL] [Abstract][Full Text] [Related]
19. Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer.
Severi G; Morris HA; MacInnis RJ; English DR; Tilley WD; Hopper JL; Boyle P; Giles GG
Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1137-41. PubMed ID: 16775172
[TBL] [Abstract][Full Text] [Related]
20. Circulating free insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: results of a case-control study involving 201 patients within a population-based screening with a 4-year interval.
Janssen JA; Wildhagen MF; Ito K; Blijenberg BG; Van Schaik RH; Roobol MJ; Pols HA; Lamberts SW; Schröder FH
J Clin Endocrinol Metab; 2004 Sep; 89(9):4391-6. PubMed ID: 15356036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
